10.26.15
Rancho Cordova, Calif.-based Cesca Therapeutics Inc.’s board of directors has appointed Michael Bruch as the company’s new chief financial officer. Cesca is an autologous cell-based regenerative medicine company.
Bruch was appointed interim chief financial officer in May 2015. Prior to that he had served as controller since joining the company in 2003. As controller he was responsible for the company’s accounting and internal control functions. He also played a key role in integrating TotipotentRX after the 2014 merger between the two companies. Bruch has over 25 years of experience in various financial and managerial roles at a number of world-class companies, including General Electric and Dada Micro Scan (now Siemens Healthcare). He is a certified public accountant and graduated with honors from California State University, Sacramento, with a bachelor of science degree in business administration.
“I am delighted that Mike has accepted the position of chief financial officer. He has done an outstanding job as Interim CFO, reinforcing our belief that he is the right person to lead the Company’s Finance function as we continue our transformation into a fully integrated regenerative medicine company.”
Bruch was appointed interim chief financial officer in May 2015. Prior to that he had served as controller since joining the company in 2003. As controller he was responsible for the company’s accounting and internal control functions. He also played a key role in integrating TotipotentRX after the 2014 merger between the two companies. Bruch has over 25 years of experience in various financial and managerial roles at a number of world-class companies, including General Electric and Dada Micro Scan (now Siemens Healthcare). He is a certified public accountant and graduated with honors from California State University, Sacramento, with a bachelor of science degree in business administration.
“I am delighted that Mike has accepted the position of chief financial officer. He has done an outstanding job as Interim CFO, reinforcing our belief that he is the right person to lead the Company’s Finance function as we continue our transformation into a fully integrated regenerative medicine company.”